Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)

NCT07647510 is registered in ClinicalTrials.gov with Dianthus Therapeutics as lead sponsor.

NCT NCT07647510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)
Lead sponsor
Dianthus Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
June 29, 2026
Completion date
September 30, 2031
Enrollment
195 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized